Record 2024 sales of €72 million
Launch of QC1, a revolutionary Quality Control system
Investment of €70 million in Ans

Ans, Monday 24 March 2025. The Trasis Group ended 2024 with sales of €72 million, a record in the history of the company, which has just celebrated its 20th anniversary. Trasis is increasingly establishing itself in the Liège region as a key player in the life science field.

4 million patients treated worldwide by 2024

“We remain deeply committed to the global fight against cancer. In 2024, we are honored to have earned the continued trust of hospitals, pharmaceutical companies, and academic research centers around the world. Our solutions supported the treatment of 4 million patients worldwide this year, contributing to a record-breaking €72 million in sales. With an operating profit of 17%, we are well-positioned to further invest in the research and development of innovative products and solutions. To support this growth, we’ve significantly expanded our team in recent years — growing from around 100 to 380 employees — primarily at our headquarters in Ans, as well as across our subsidiaries in the United States and France”, explains Gauthier Philippart, co-founder and CEO of Trasis.

Unique Belgian expertise in nuclear medicine

As world leader, Trasis is a unique company in the field of radiochemistry and nuclear medicine: it brings together all the skills in-house and supplies the equipment and ingredients needed for its customers to produce the radiopharmaceuticals used in hospitals, particularly for PET scans. “Innovation drives everything we do. With a dedicated team of over 100 professionals in Research & Development, we support our customers across the entire value chain — from the formulation of active substances to the delivery of life-saving treatments to patients. We help our customers to ensure a complete chain of supply and expertise, from the formulation of active substances to the administration of these drugs to patients”, explains Jean-Luc Morelle, co-founder and CTO of Trasis.

Nuclear medicine is revolutionising the field of oncology. It plays a crucial role in both diagnosing cancers and treating some of them. After a simple injection of a radiopharmaceutical, it is possible to scan the entire body for cancer cells, enabling exhaustive detection of metastases. The radiopharmaceuticals used in nuclear medicine accumulate specifically in cancer cells, delivering radiation directly to the source of the disease. This approach minimises damage to surrounding healthy tissue, thereby reducing side effects. It has contributed to a significant increase in survival rates for certain cancers, such as neuroendocrine tumours, where the five-year survival rate has risen from 20% to around 80%.

“Trasis solutions are used in hospitals and research centers around the globe — but Belgian patients are among the very first to benefit from them, notably at the CHU Liège, UZ Leuven, UZ Antwerpen, CHR Namur, Bruxelles Imaging Pharmacy (BIP), Institut Jules Bordet and UZ Gent, to name but a few”, adds Jean-Luc Morelle.

QC1 – A revolutionary new system

In 2025, Trasis is launching “QC1”, an all-in-one Quality Control system. As the result of 8 years of Research and Development, this equipment performs more than 14 analyses in parallel in an integrated, automated system, where more than 7 different pieces of equipment are needed today. Thanks to this innovative tool, the production of radiopharmaceuticals is faster, safer and less expensive. All to the benefit of patients and the overall healthcare budget.

“Quality control is a critical aspect of our industry, especially as radiopharmaceuticals are produced in small batches and in real time. Our new solution, QC1, is set to revolutionize this process by delivering precision, speed, and efficiency — all in a compact format. With just one sample, one click, and a comprehensive report, QC1 simplifies a traditionally complex procedure into a streamlined operation lasting only a few minutes. Initial feedback from the first 15 units being tested by our partners has been highly encouraging, and demand is already strong. We believe QC1 has the potential to become a future blockbuster. Confident in its promise, we’ve taken bold steps and made significant investments to bring this innovation to life”, explains CEO Gauthier Philippart.

Investment of €70 million to pursue innovation and create 350 new jobs

To support its continued growth while reinforcing both its European reach and local roots, Trasis is investing €70 million in new production facilities just one kilometer from its headquarters in Ans, near Liège. The project will unfold in two phases: €40 million by 2027, followed by an additional €30 million by 2030. The new site will revitalize a 6-hectare former industrial wasteland, strategically located near Ans station and acquired by Trasis several years ago.

By 2027, new buildings will occupy around 8,000 m² of floor space. They are expected to create 350 additional jobs, mainly in manufacturing.

Gauthier Philippart, CEO, explains: “We foresee strong growth in our business, particularly in the production of ingredients for radiopharmaceuticals — a promising opportunity that aligns perfectly with the site’s industrial zoning. As a local, family-owned company, we’re proud to contribute actively to the reindustrialization of our region. The new site is strategically multimodal, offering easy access via Ans train station, the future high-service Busway, and the RAVeL greenway and cycle route — all sustainable transport options that will benefit our employees. Notably, 80% of our team comes from the Liège area, with 40% living within 10 kilometers of the site. By investing in Belgium, we’re not only strengthening our local presence but also positioning ourselves to capture new export market opportunities — always in the service of life and health.”

Recognition

As 2025 begins, Trasis and its founders are receiving significant recognition, with nominations for several prestigious entrepreneurial awards. In January, they were named finalists for the esteemed Manager of the Year award. Trasis is also a finalist in the Trends Gazelles 2025 awards for the province of Liège, in the Large Company category. Additionally, Gauthier Philippart has been selected by the Sud Presse editorial team as one of five finalists for the 2025 “Liégeois de l’année” award in the Economy category.

About Trasis

TRASIS is a global leader in nuclear medicine, specializing in the design and manufacture of advanced equipment for the diagnosis and treatment of cancer and neurodegenerative diseases — a field experiencing strong and growing demand. The group operates across three key market segments in over 60 countries: hospital nuclear medicine departments, research centers and radiopharmaceutical companies, and the production of active ingredients and sterile substances for the pharmaceutical industry. In 2024, Trasis achieved €72 million in sales. The company employs approximately 380 people across Belgium, France, the United States, and other locations, with over 98% of its production destined for export. In addition to its core business, Trasis actively supports the biotech and medtech ecosystem by investing in and mentoring three local start-ups. Learn more at www.trasis.com.

Media contact

Photos in high resolution are available here : https://we.tl/t-hkNRdnB0u5

communication@trasis.com
Melyssa Muce, management assistant : muce@trasis.com +32 475 76 44 86
Jacques Galloy, board member : galloy@trasis.com

2024: a record-breaking year for Trasis